alexa LPS/endotoxins Molecular Diversity Impacting Vaccines And Adjuvants Activities And Toxicity
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Alexey Novikov and Martine Caroff
LPS-Biosciences, France
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Abstract
Endotoxins are major antigens of the Gram negative bacterial membrane. Their use in vaccines is known for years, both for their antigenic properties and for their immuno modulator capacities used in vaccine adjuvants. Endotoxins are mixtures of lipopolysaccharides (LPS), made of a lipidic moiety, “lipid A” anchored in the membrane, to which an oligosaccharide core is substituted, in Smooth-type bacteria, by a long chain of repetitive oligosaccharide units, extending outside of the membrane. This high-specific chain named O-chain, is unique for a given bacterium, thus characteristic of each serotype of a given species, and efficiently used as an antigen for vaccines or for bacterial detection tests. As for the glycol-phospho-lipid lipid A region, it is responsible for most of the toxic and beneficial properties of LPS. All endotoxins are LPS, but all LPS are not toxic. Different biochemical methods have been described for detoxifying LPS molecules. The most efficient and recognized one is the lipid A glycophosphate release under mild acid conditions. This leads to mono-phosphoryl-lipid A (MPLA) production. This process, when completed by de-O-acylation, results in the well-known MPL© adjuvant commercialized by GSK and used in a new vaccines generation. During more than forty years, researchers working now at LPS-BioSciences have established tens of lipid A structures from different bacterial species. Our structure to activity studies has shown that each structural element can have a drastic impact on LPS biological activities. We have also described a number of naturally non-toxic LPS structures. We will show how heterogeneous and variable lipid A structures can be due to culture conditions, strains, etc., with a major impact on their biological activities. The methods used for LPS extraction and structural characterization are thus crucial for understanding the structure to activity relationships and mastering their activities for a safe use.
Biography

Alexey Novikov is working as the Head of R&D at LPS-BioSciences Company, a start-up created in 2011 by Martine Caroff. He also has 10 years of experience in academic research in the field of bacterial lipopolysaccharides. He has done his Master’s in physical properties of endotoxins, their extraction methods and their structural characterization by mass spectrometry. He is the author of 50 papers published in reputed journals. He has his expertise in Physics, Chemistry and Biochemistry.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords